Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here ...

A new treatment was recently approved by the FDA for patients who are having difficulty using eye drops. An iDose implant can be inserted in the eye to slowly release medicine. Glaucoma specialist ...

that it had failed to take sufficient steps to prevent microbial contamination at a key facility that makes eye drops and many other medicines that require sterile production. In a Feb. 24 warning ...

The Laser Vision Correction Center of New Jersey recently announced it is the first practice in the state to offer the only treatment approved by ... therapy is the first FDA-authorized treatment ...

The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved an expanded ... affecting the posterior segment of the eye ...

Betaliq’s EyeSol technology offers increased bioavailability and a drop size of 10 microliters that can be replicated in the Optejet device. The EyeSol technology is currently used and licensed in FDA ...